AEQUITA PHARMACY Recalls

All product recalls associated with AEQUITA PHARMACY.

Get alerts for this brand

Recall Summary

Total Recalls

13

Past Year

13

Class I (Serious)

0

Most Recent

Jul 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1–13 of 13 recalls

Tirzepatide Niacinamide Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Tirzepatide + Niacinamide Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025

MA

• AEQUITA PHARMACY

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Tirzepatide + Niacinamide 16.6 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Tirzepatide + Niacinamide 13.2 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Tirzepatide + Niacinamide 11.24 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Semaglutide + Cyanocobalamin Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Tirzepatide Niacinamide Injection (Aequita) – Processing Controls (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Tirzepatide + Niacinamide 8.8 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Lack of Processing Controls.

Class IIModerate

FDAJul 18, 2025MA• AEQUITA PHARMACY

Stay Informed

AEQUITA PHARMACY Recalls

Recall Summary

Tirzepatide Niacinamide Injection (Aequita) – Processing Controls (2025)

Tirzepatide + Niacinamide Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Tirzepatide + Niacinamide 16.6 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Tirzepatide + Niacinamide 13.2 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Semaglutide Cyanocobalamin Injection (Aequita) – Processing Controls (2025)

Tirzepatide + Niacinamide 11.24 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Semaglutide + Cyanocobalamin Injection (Aequita Pharmacy) – Processing Controls Issue (2025)

Tirzepatide Niacinamide Injection (Aequita) – Processing Controls (2025)

Tirzepatide + Niacinamide 8.8 mg Injection (Aequita Pharmacy) – Processing Controls Issue (2025)